Skip to main content
Log in

Human astrocytic brain tumors express APO2L/TRAIL

  • Express communication
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

APO2 ligand (APO2L) is a CD95 ligand (CD95L)-related cytokine of the tumor necrosis factor family that interacts with agonistic (DR4, DR5) and antagonistic (DcR1, DcR2) receptors. Cultured malignant glioma cells preferentially express agonistic receptors and are susceptible to APO2L-induced apoptosis. Here, we report that 8 of 8 human glioma cell lines expressed APO2L mRNA and protein in vitro. Immunohistochemistry using a monoclonal antibody to APO2L revealed that all 23 primary astrocytic brain tumors analyzed, including low-grade astrocytomas and glioblastomas, express APO2L in vivo. With the exception of reactive astrocytes, non-neoplastic glia and neurons in the cerebrum lacked immunoreactivity of APO2L. Thus, in addition to the CD95/CD95L system, a second death ligand/death receptor pair may regulate susceptibility to apoptosis in human glial neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 19 August 1998 / Accepted: 14 September 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rieger, J., Ohgaki, H., Kleihues, P. et al. Human astrocytic brain tumors express APO2L/TRAIL. Acta Neuropathol 97, 1–4 (1999). https://doi.org/10.1007/s004010050948

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004010050948

Navigation